Idexx Laboratories
IDXX · What the business does, what can go wrong, and how options sellers approach it
What it does
Idexx Laboratories makes diagnostic tools for animal health. Its main customers are veterinary clinics, which use its products to test pets for illness and monitor ongoing conditions. The company also serves livestock and other animal markets, and it sells practice management software.
Its offerings include in-clinic analyzers, single-use test kits for dogs and cats, and reference laboratories that process samples sent by clinics.
How it makes money
Idexx earns money from three sources. It sells instruments to clinics, it sells the consumable tests and supplies those instruments use, and it charges for lab testing and software services.
Once a clinic installs an analyzer, it keeps buying the consumables to run it. Lab services and software tend to bring in repeat business as well.
Why investors own it
Investors often view Idexx as a way to own long-term growth in pet care. Pet owners have generally been willing to spend on veterinary care, and diagnostics are a routine part of many visits. The installed base of instruments creates switching costs, since clinics build workflows around them. Its business is concentrated in diagnostics rather than spread across unrelated industries.
What can go wrong
- Fewer veterinary visits, often when household budgets tighten, would reduce testing volume.
- Competitors may take share or pressure pricing.
- Currency swings affect results because part of its sales come from abroad.
- The stock has often traded at a premium to the market, so disappointments can hit it hard.
- Clinic consolidation into large chains could shift bargaining power toward customers.
What to watch
- Same-clinic testing volumes and visit trends
- Recurring revenue from consumables and lab services
- Placements of new instruments
- Pricing trends
- Operating margin
- Competitive product launches
- Currency effects on reported results
Options income angle
Options on IDXX are available across several expirations but are typically less liquid than mega-cap names. Spreads can be wider away from the current price, and open interest and volume vary by strike and expiration.
Implied volatility tends to build into quarterly earnings and often drops afterward.
One caution: the stock can gap sharply after earnings. A covered call can cap gains if shares rally, and a short put can lead to a large loss if shares fall well past the strike.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
IDEXX reported double-digit revenue growth and a larger gain in operating profit in 2025, driven by recurring diagnostic testing and a successful new instrument launch. The filing also says fewer visits to U.S. veterinary clinics held back volume growth, and management expects a similar decline in 2026. It also flags dependence on a few large corporate customers and competitors, and a CEO transition planned for May 2026.
How the business did
- Revenues rose 10.4%, and organic revenue growth (growth excluding currency swings and acquisitions) was 9.6%. Income from operations rose 20.5%. Gross profit margin rose by 80 basis points (a basis point is one hundredth of a percentage point).
- General and administrative expense fell 8.5%, mainly because the prior year included a $61.5 million expense for a litigation matter that is now concluded.
- In the Companion Animal Group (CAG), IDEXX VetLab consumables revenue rose 14.8% and instrument revenue rose 51.8%, helped by the new IDEXX inVue Dx Analyzer. Rapid assay revenue fell 3.0%, as customers shifted pancreatic lipase testing to the Catalyst instrument. Recurring diagnostic revenue was approximately 79% of consolidated revenue.
- Livestock, Poultry and Dairy segment income from operations fell 51.3%, with gross margin down 260 basis points on higher product costs. Water gross margin fell 100 basis points.
- Operating cash flow was $1.2 billion, up $252.8 million. The company paid approximately $80 million to conclude the litigation matter and used $379.9 million more cash on share repurchases than in 2024.
Risks specific to this company
- Customer consolidation: More veterinary hospitals are owned by corporations, such as Mars (Banfield, Blue Pearl, VCA) and National Veterinary Associates. Mars also runs reference labs and sells competing point-of-care instruments, and acquired hospitals may shift testing away from IDEXX.
- Single-source suppliers: Many products and components come from sole or single sources, such as Ortho, and some cannot easily be replaced. Many major products are made in Southern Maine, so a disruption there could hurt supply.
- Currency: About 36% of revenue came from customers outside the U.S., and approximately 23% of consolidated revenue came from products made or sourced in U.S. dollars and sold in local currencies. A stronger dollar reduces those sales and profits, and hedges are designed to delay, not eliminate, the effect.
- Fewer clinic visits: U.S. same-store clinical visits declined approximately 2% in 2025, and pet owners generally pay for veterinary care out of pocket, so economic weakness can reduce testing.
- Debt: Credit Facility borrowings were $398.0 million and carry variable rates tied to SOFR. A covenant caps the ratio of debt to adjusted earnings at 3.5-to-1, and the company reported being in compliance.
- Leadership change: The filing describes a planned CEO transition in May 2026, announced January 13, 2026, and notes it could bring management challenges.
What management is watching
- U.S. clinic activity: The initial 2026 outlook anticipates a similar decline in U.S. same-store clinical growth as in 2025, which management attributes to veterinary practice capacity limits and macroeconomic headwinds.
- Spending and buybacks: Projected 2026 capital expenditures are approximately $180.0 million, covering manufacturing and operations facilities and customer-facing software. Management anticipates a 1% to 2% reduction in diluted shares through repurchases, subject to market conditions.
- Debt and taxes: The $75.0 million 2026 Senior Notes are due September 4, 2026, and the projected 2026 effective tax rate is approximately 21.3%, up from 20.0% in 2025.
- Tariffs and trade: Management says changes in tariff and trade policies could raise costs, cut margins or make products less available in some regions.
- Measures pointed to: Organic revenue growth, Adjusted EBITDA, net debt, and the installed base of premium instruments, which grew 12%.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 2, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
IDEXX reported third-quarter revenue growth of 9.9%, or 10.0% on an organic basis, with income from operations up 13.4%. Growth came mainly from recurring diagnostic testing in the Companion Animal Group (CAG), through higher volumes and higher prices. Profit margins widened, even as general and administrative costs grew faster than revenue.
How the business did
- Quarter: Gross profit margin was 62.9%, a 110 basis point increase (a basis point is one hundredth of a percentage point). Income from operations was 33.1% of revenue. CAG revenue grew 10.2%. IDEXX VetLab consumables, the tests run on the company's in-clinic instruments, grew 14.3%, helped by 11% growth in the installed base of premium instruments. Rapid assay products grew only 0.6%, and instrument revenue was relatively constant because higher placements were offset by lower pricing. Water revenue grew 8.4% and Livestock, Poultry and Dairy (LPD) grew 2.6%.
- Nine months: Revenue grew 11.2%, or 10.0% organic, and income from operations grew 14.0%. Currency added 1.1% to revenue growth.
- Costs and unusual items: General and administrative expense rose 16.4% in the quarter, driven by consulting fees, compensation and technology-related depreciation. The nine-month figures include a $5 million expense for the full impairment of an equity investment and the comparison against an approximately $9 million prior-year reduction in a litigation accrual. The company bought CoVet, a software business, on September 15, 2026. Its revenue impact was immaterial.
- Cash and capital: Operating cash flow for nine months was $1,063.1 million, up $237.1 million, partly because the prior year included a payment of approximately $80 million to conclude a litigation matter. Cash used for share repurchases was $169.2 million lower than a year earlier. Outstanding Credit Facility borrowings were $474.0 million, and the company repaid $75.0 million of 2026 Senior Notes at maturity.
What management is watching
- Tax rate: The company expects smaller share-based compensation tax benefits in the fourth quarter, which raises its effective tax rate for 2026. The rate was 20.6% in the quarter.
- Spending and debt: The 2026 capital expenditure plan is approximately $160.0 million, covering manufacturing and operations facilities and customer-facing software. The $75.0 million 2027 Series B Notes fall due February 12, 2027, to be repaid from cash, Credit Facility borrowings, new notes, or a combination. The consolidated leverage ratio was 0.5-to-1 against a covenant limit of 3.5-to-1.
- Costs from conflict: Conflicts in the Middle East have raised fuel prices, which increase freight and distribution costs. Management also says they could disrupt supply chains and affect demand and currency rates.
- Measures cited: Management points to organic revenue growth, which strips out currency and certain acquisitions and divestitures, and to segment income from operations, which excludes foreign currency transaction gains and losses. The MD&A gives no revenue or earnings outlook for the rest of the year.
Follow IDXX in Kortex
The Kortex app shows IDXX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.